by Kam-Ming Au. / Thesis (M.Sc.)--Chinese University of Hong Kong, 1990. / Bibliography: leaves 87-101. / LIST OF TABLES / LIST OF FIGURES / ACKNOWLEDGEMENTS / ABSTRACT / Chapter CHAPTER 1. --- INTRODUCTION --- p.1 / Chapter 1.1 --- Normal calcium homeostasis --- p.1 / Chapter 1.2 --- The incidence and common causes of hypercalcemia in hospital population --- p.6 / Chapter 1.3 --- Hypercalcemia in primary hyperparathyroidism --- p.10 / Chapter 1.4 --- Hypercalcemia of malignancy --- p.13 / Chapter 1.5 --- Pathophysiology of humoral hypercalcemia of malignancy --- p.16 / Chapter 1.6 --- Pathogenesis of humoral hypercalcemia of malignancy-evidence for a parathyroid hormone-related peptide --- p.20 / Chapter 1.7 --- Hypercalcemia in primary hepatocellular carcinoma --- p.27 / Chapter 1.8 --- Physiological role of cyclic adenosine monophosphate --- p.28 / Chapter 1.9 --- Aim of the present study --- p.29 / Chapter CHAPTER 2. --- MATERIALS AND METHODS --- p.30 / Chapter 2.1 --- Patients --- p.30 / Chapter 2.1.1 --- Hepatocellular carcinoma patients --- p.30 / Chapter 2.1.2 --- Cirrhotic patients --- p.30 / Chapter 2.2 --- Healthy control subjects --- p.30 / Chapter 2.3 --- Collection of blood and urine specimens --- p.32 / Chapter 2.4 --- Methods --- p.32 / Chapter 2.4.1 --- Routine chemistries --- p.32 / Chapter 2.4.2 --- Plasma and urine cyclic adenosine monophosphate --- p.33 / Chapter - --- commercial urine controls --- p.34 / Chapter - --- scintillation cocktail --- p.34 / Chapter - --- imprecision study --- p.34 / Chapter - --- accuracy study --- p.34 / Chapter 2.4.3 --- Nephrogenous cyclic adenosine monophosphate and total urinary cyclic adenosine monophosphate / 100 ml glomerular filtrate --- p.35 / Chapter 2.4.4 --- Total urinary cyclic adenosine monophosphate : creatinine ratio --- p.36 / Chapter 2.4.5 --- Components of hypercalcemia --- p.36 / Chapter 2.4.6 --- Urinary hydroxyproline : creatinine ratio --- p.37 / Chapter 2.4.7 --- Renal phosphate threshold --- p.37 / Chapter 2.4.8 --- Serum parathyroid hormone --- p.38 / Chapter 2.4.9 --- Serum parathyroid hormone-related peptide --- p.38 / Chapter 2.5 --- Statistical analysis --- p.39 / Chapter CHAPTER 3. --- RESULTS --- p.40 / Chapter 3.1 --- Method validation for cyclic adenosine monophosphate assay --- p.40 / Chapter 3.1.1 --- Standard curve of the cyclic adenosine monophosphate assay --- p.40 / Chapter 3.1.2 --- Results of imprecision study --- p.43 / Chapter 3.1.3 --- Results of accuracy study --- p.43 / Chapter 3.2 --- "Results of hypercalcemic and normocalcemic hepatocellular carcinoma patients, cirrhotic patients, and healthy control subjects" --- p.47 / Chapter 3.2.1 --- "Results of serum calcium, albumin adjusted calcium, serum albumin and serum alkaline phosphatase" --- p.47 / Chapter 3.2.2 --- "Results of serum phosphate, renal phosphate threshold and serum parathyroid hormone" --- p.51 / Chapter 3.2.3 --- Results of plasma cyclic adenosine monophosphate --- p.55 / Chapter 3.2.4 --- "Results of nephrogenous cyclic adenosine monophosphate , total urinary cyclic adenosine monophosphate / 100 ml glomerular filtrate and total urinary cyclic adenosine monophosphate : creatinine ratio 59" / Chapter 3.2.5 --- Results of urinary calcium : creatinine ratio and urinary hydroxyproline : creatinine ratio --- p.66 / Chapter 3.2.6 --- Factors contributing to hypercalcemia in hepatocellular carcinoma patients 71 / Chapter 3.2.7 --- Results of serum parathyroid hormone-related peptide --- p.75 / Chapter CHAPTER 4. --- DISCUSSION --- p.77 / REFERENCES --- p.87
| Identifer | oai:union.ndltd.org:cuhk.edu.hk/oai:cuhk-dr:cuhk_318564 |
| Date | January 1990 |
| Contributors | Au, Kam-Ming., Chinese University of Hong Kong Graduate School. Division of Clinical and Pathological Sciences. |
| Publisher | Chinese University of Hong Kong |
| Source Sets | The Chinese University of Hong Kong |
| Language | English |
| Detected Language | English |
| Type | Text, bibliography |
| Format | print, 101 leaves : ill. ; 30 cm. |
| Rights | Use of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
Page generated in 0.0021 seconds